JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB266322

Human UBE2A knockout HEK-293T cell line

Be the first to review this product! Submit a review

|

(0 Publication)

UBE2A KO cell line available to order. KO validated. Free of charge wild type control available. Knockout achieved by using CRISPR/Cas9, 19 bp deletion in exon 1 and 8 bp deletion in exon 1. To order both knockout and wild-type control cells: select '2 x 1000000 Cells/vial'. To order only knockout cells: select '1000000 Cells/vial'.
3 Images
Sanger Sequencing - Human UBE2A knockout HEK-293T cell line (AB266322)
  • Sanger seq

Unknown

Sanger Sequencing - Human UBE2A knockout HEK-293T cell line (AB266322)

Allele-1 : 19 bp deletion in exon 1

Sanger Sequencing - Human UBE2A knockout HEK-293T cell line (AB266322)
  • Sanger seq

Lab

Sanger Sequencing - Human UBE2A knockout HEK-293T cell line (AB266322)

Sequencing chromatogram displaying sequence edit in exon 1

Sanger Sequencing - Human UBE2A knockout HEK-293T cell line (AB266322)
  • Sanger seq

Unknown

Sanger Sequencing - Human UBE2A knockout HEK-293T cell line (AB266322)

Allele-2 : 8 bp deletion in exon 1.

Key facts

Cell type

HEK-293T

Species or organism

Human

Tissue

Kidney

Form

Liquid

form

Knockout validation

Sanger Sequencing

Mutation description

Knockout achieved by using CRISPR/Cas9, 19 bp deletion in exon 1 and 8 bp deletion in exon 1

Product details

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab266322-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab255449 Human wild-type HEK-293T cell line", "number":"AB266322-CMP02" }, { "size":"1 x 1000000 Cells/vial", "name":"ab266322 Human UBE2A knockout HEK-293T cell line", "number":"AB266322-CMP01" } ] }, "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab266322-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab266322 Human UBE2A knockout HEK-293T cell line", "number":"AB266322-CMP01" }, { "size":"1 x 1000000 Cells/vial", "name":"ab255449 Human wild-type HEK-293T cell line", "number":"AB266322-CMP02" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab266322-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab266322 Human UBE2A knockout HEK-293T cell line", "number":"AB266322-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab266322-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab266322 Human UBE2A knockout HEK-293T cell line", "number":"AB266322-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
UBE2A
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing
Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium

DMEM (High Glucose) + 10% FBS

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

Rad6 also known as ubiquitin-conjugating enzyme E2 A (UBE2A) is an enzyme with a molecular weight of approximately 17 kDa. This enzyme plays an essential role in the ubiquitination process where it catalyzes the transfer of ubiquitin to substrate proteins. Rad6 is expressed in various tissues with significant activity observed in the testis and brain suggesting its involvement in cell division and development.
Biological function summary

Rad6 functions as part of a larger protein complex involved in the DNA damage repair process. It collaborates with the RAD6 epistasis group which ensures the maintenance of genomic stability. Rad6 as a ubiquitin-conjugating enzyme interacts with E3 ubiquitin ligases facilitating the ubiquitination of target proteins that require degradation or regulation in response to DNA damage. This activity is vital for DNA repair mechanisms like post-replication repair (PRR) which protects cells from mutagenic events.

Pathways

Rad6 integrates into critical biological processes including the ubiquitin-proteasome pathway and the DNA repair pathway. Within the ubiquitin-proteasome system Rad6 aids in tagging proteins for degradation thereby regulating protein levels and cellular functions. It connects to other proteins like E3 enzymes and RAD18 in the DNA repair pathway. Its activity in DNA repair ensures the appropriate response to DNA damage coordinating with other mechanistic proteins to maintain genomic stability.

Rad6 shows significant association with cancer and neurodegenerative conditions. Changes in Rad6 activity can lead to abnormal cell cycle progression contributing to oncogenesis particularly in breast and ovarian cancers. Rad6 interacts with proteins such as BRCA1 a tumor suppressor implicating its role in hereditary breast cancer. Additionally its dysfunction in the brain may relate to Alzheimer's disease highlighting its connection to neuroprotective pathways and protein degradation systems.

Quality control

STR analysis

TPOX, CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com